Related Experiment Video

Updated: Mar 6, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K

A Review of mTOR Pathway Inhibitors in Gynecologic Cancer

Andréia Cristina de Melo1, Eduardo Paulino1, Álvaro Henrique Ingles Garces1

  • 1Brazilian National Cancer Institute (INCA), Rio de Janeiro, RJ, Brazil.

Oxidative Medicine and Cellular Longevity
|March 14, 2017
PubMed

Insights

Targeting the PI3K/AKT/mTOR pathway offers a promising avenue for treating advanced gynecologic cancers. Further research into mTOR pathway inhibitors is crucial for developing more effective targeted therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced gynecologic cancers often have limited treatment options and a poor prognosis.
  • Current systemic therapies, despite advancements in targeted drugs, show limited antitumor efficacy.
  • The PI3K/AKT/mTOR pathway is critical for cancer cell survival, growth, and proliferation.

Purpose of the Study:

  • To review the potential impact of mTOR pathway inhibitors in gynecologic cancer treatment.
  • To highlight the need for rationally designed targeted therapies in this field.
  • To underscore the importance of investigating PI3K/AKT/mTOR pathway-targeted therapies.

Main Methods:

  • Literature review of existing evidence on mTOR pathway inhibitors in gynecologic cancers.
  • Analysis of the role of the PI3K/AKT/mTOR pathway in endometrial, cervical, and ovarian cancers.
  • Synthesis of current research on targeted therapies for advanced gynecologic malignancies.

Main Results:

  • The PI3K/AKT/mTOR pathway is frequently dysregulated in gynecologic cancers.
  • mTOR pathway inhibitors represent an attractive therapeutic target due to the pathway's central role in cancer.
  • Limited recent advances necessitate novel treatment strategies.

Conclusions:

  • Targeting the PI3K/AKT/mTOR pathway holds significant therapeutic potential for gynecologic cancers.
  • Rationally designed molecularly targeted therapies, particularly mTOR inhibitors, are an emerging option.
  • Further investigation into PI3K/AKT/mTOR pathway-targeted therapies is warranted for improved patient outcomes.

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Stereotactic Radiosurgery for Gynecologic Cancer10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K